水野孝昭 (Mizuno Takaaki) - マイポータル

基本情報

所属: 慶應義塾大学医学部がんゲノム医療センター特任助教（有期）
: 株式会社CLINIAL 代表取締役社長
: 国立研究開発法人国立がん研究センター中央病院先端医療科外来研究員

学位: 博士（医学）(2021年3月東京慈恵会医科大学)
学士（医学）(2012年3月名古屋市立大学)

J-GLOBAL ID: 202401008387010110
researchmap会員ID: R000074024

研究キーワード

研究分野

経歴

2023年4月 - 現在

慶應義塾大学医学部, がんゲノム医療センター, 特任助教
2021年4月 - 2023年3月

国立研究開発法人国立がん研究センター, 中央病院, 先端医療科チーフレジデント
2018年4月 - 2021年3月

国立研究開発法人国立がん研究センター, 中央病院, 内科レジデント
2012年4月 - 2018年3月

小牧市民病院, 呼吸器内科, 医員

委員歴

2024年4月 - 現在

防衛医科大学校病院臨床研究審査委員会, 審査委員
2023年10月 - 現在

厚生労働省, がんゲノム医療中核拠点病院等連絡会議WG構成員

受賞

論文

Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations

Kaneko S., Takasawa K., Asada K., Shiraishi K., Ikawa N., Machino H., Shinkai N., Matsuda M., Masuda M., Adachi S. …

Molecular Cancer 23(1) 126-126 2024年12月
Multi-omics and clustering analyses reveal the mechanisms underlying unmet needs for patients with lung adenocarcinoma and identify potential therapeutic targets.

Ken Asada, Syuzo Kaneko, Ken Takasawa, Kouya Shiraishi, Norio Shinkai, Yoko Shimada, Satoshi Takahashi, Hidenori Machino, Kazuma Kobayashi, Amina Bolatkan …

Molecular cancer 23(1) 182-182 2024年9月2日
Characterizing multi-PIK3CA mutations across cancer types: Toward precision oncology

Nakamura K., Ishikawa M., Kawano R., Aimono E., Mizuno T., Nohara S., Tanishima S., Hayashi H., Nishihara H., Yamada H. …

Cancer Medicine 13(14) e70052 2024年7月
Advances in cancer DNA methylation analysis with methPLIER: use of non-negative matrix factorization and knowledge-based constraints to enhance biological interpretability

Takasawa K., Asada K., Kaneko S., Shiraishi K., Machino H., Takahashi S., Shinkai N., Kouno N., Kobayashi K., Komatsu M. …

Experimental and Molecular Medicine 56(3) 646-655 2024年3月
Sketch-based semantic retrieval of medical images

Kobayashi K., Gu L., Hataya R., Mizuno T., Miyake M., Watanabe H., Takahashi M., Takamizawa Y., Yoshida Y., Nakamura S. …

Medical Image Analysis 92 2024年2月
BRCA1/2 reversion mutations in a pan-cancer cohort

Nakamura K., Hayashi H., Kawano R., Ishikawa M., Aimono E., Mizuno T., Kuroda H., Kojima Y., Niikura N., Kawanishi A. …

Cancer Science 115(2) 635-647 2024年2月
Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients

Satake T., Kondo S., Tanabe N., Mizuno T., Katsuya Y., Sato J., Koyama T., Yoshida T., Hirata M., Yamamoto N.

Cancer Research Communications 3(11) 2302-2311 2023年11月
Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials

Takamizawa S., Katsuya Y., Chen Y.N., Mizuno T., Koyama T., Sudo K., Yoshida T., Kondo S., Iwasa S., Yonemori K. …

Investigational New Drugs 41(1) 173-181 2023年2月
Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice

Ida H., Koyama T., Mizuno T., Sunami K., Kubo T., Sudo K., Tao K., Hirata M., Yonemori K., Kato K. …

Cancer Science 113(12) 4300-4310 2022年12月
Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China

Mizuno T., Katsuya Y., Sato J., Koyama T., Shimizu T., Yamamoto N.

Frontiers in Oncology 12 2022年8月26日
Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report

So C., Yoshida T., Mizuno T., Yatabe Y., Ohe Y.

Thoracic Cancer 13(9) 1423-1426 2022年5月
Study protocol for NCCH1908 (UPFRONT-trial): A prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients

Mizuno T., Yoshida T., Sunami K., Koyama T., Okita N., Kubo T., Sudo K., Shimoi T., Ueno H., Saito E. …

Japanese Journal of Clinical Oncology 51(12) 1757-1760 2021年12月1日
Smoking history predicts high presence of tils and efficacy of pd-1 blockade in pd-l1 expression-negative non-small cell lung cancer patients

SHIMODA Y., YOSHIDA T., SHIRASAWA M., MIZUNO T., JO H., MATSUMOTO Y., SHINNO Y., OKUMA Y., GOTO Y., HORINOUCHI H. …

Anticancer Research 41(11) 5739-5747 2021年11月
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer.

Takaaki Mizuno, Yuki Kojima, Kan Yonemori, Hiroshi Yoshida, Yukiko Sugiura, Yohei Ohtake, Hitomi S Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo …

Oncology letters 20(6) 336-336 2020年12月
HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix.

Takaaki Mizuno, Yuki Kojima, Kan Yonemori, Hiroshi Yoshida, Yukiko Sugiura, Yohei Ohtake, Hitomi S Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo …

Oncology letters 20(4) 38-38 2020年10月
Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure.

Takaaki Mizuno, Hidehito Horinouchi, Sho Watanabe, Jun Sato, Ryo Morita, Shuji Murakami, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Noboru Yamamoto …

Thoracic cancer 11(4) 1038-1044 2020年4月
Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis.

Ken Masuda, Yutaka Fujiwara, Yuki Shinno, Takaaki Mizuno, Jun Sato, Ryo Morita, Yuji Matsumoto, Shuji Murakami, Yasushi Goto, Shintaro Kanda …

Journal of thoracic disease 11(7) 2965-2972 2019年7月
Comparison between stereotactic radiosurgery and whole-brain radiotherapy for 10-20 brain metastases from non-small cell lung cancer.

Takaaki Mizuno, Kazuto Takada, Toshinori Hasegawa, Tatsuya Yoshida, Kenta Murotani, Hironori Kobayashi, Tsutomu Sakurai, Yuuki Yamashita, Nana Akazawa, Eiji Kojima

Molecular and clinical oncology 10(5) 560-566 2019年5月
Next-Generation Sequencer Analysis of Pulmonary Pleomorphic Carcinoma With a CD74-ROS1 Fusion Successfully Treated With Crizotinib.

Takaaki Mizuno, Yutaka Fujiwara, Kazushi Yoshida, Takashi Kohno, Yuichiro Ohe

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 14(5) e106-e108 2019年5月
A propensity score-matched comparison of the efficacies of OK-432 and talc slurry for pleurodesis for malignant pleural effusion induced by lung adenocarcinoma.

Kango Nohara, Kazuto Takada, Eiji Kojima, Kiyoko Ninomiya, Shoko Miyamatsu, Takahiro Shimizu, Tsutomu Sakurai, Takaaki Mizuno, Yuuki Yamashita

Respiratory investigation 54(5) 341-6 2016年9月

もっとみる

MISC

Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome-wide association and whole genome sequencing analyses

Shiraishi K., Takahashi A., Momozawa Y., Daigo Y., Kaneko S., Kawaguchi T., Kunitoh H., Matsumoto S., Horinouchi H., Goto A. …

Cancer Communications 44(2) 287-293 2024年2月